% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • robertvince robertvince Jul 12, 2012 9:11 AM Flag

    Alnylam, Ascletis form strategic collaboration to develop ALN-VSP

    Alnylam Pharmaceuticals and Ascletis Pharmaceuticals have formed a strategic collaboration for the development of ALN-VSP, a first-in-class, systemically delivered RNAi therapeutic for the treatment of liver cancers including hepatocellular carcinoma (HCC), a significant area of unmet need in China. Per the terms of the agreement, Ascletis has received an exclusive license from Alnylam to develop and commercialize ALN-VSP in China including Hong Kong, Macau, and Taiwan. The initial focus will be on advancing ALN-VSP into a Phase II study for the treatment of HCC. Ascletis will diligently advance ALN-VSP, and as the program progresses, Ascletis will pay Alnylam development and commercial milestones and royalties on net sales in the Ascletis territory. Alnylam retains all rights to develop and commercialize the product in the rest of the world. Alnylam may use the data generated in China by Ascletis under this strategic collaboration for development of ALN-VSP in the rest of the world, and Ascletis may potentially receive sublicense payments based on any such future partnerships.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
70.55-1.01(-1.41%)3:25 PMEDT